Navigation Links
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
Date:10/26/2008

- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs -

NEW HAVEN, Conn., Oct. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial with the oral form of its compound, radezolid (RX-1741), for the treatment of uncomplicated skin and skin structure infections (uSSSI). These results were announced at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting (2008 ICAAC/IDSA Joint Meeting) held October 25 - 28 in Washington, D.C.

The open-label trial met both its primary (efficacy) and secondary (safety) endpoints. All doses of radezolid were as efficacious as linezolid (Zyvox(R), currently marketed by Pfizer) and demonstrated a good safety profile. The study also showed that radezolid was approximately four times more potent than linezolid against bacteria cultured from subjects in the study, including against methicillin-resistant Staphylococcus aureus (MRSA), with MIC90s of 0.5mg/L and 2.0mg/L respectively. MIC90s for other relevant bacterial isolates in the study were 0.5mg/L and 2.0mg/L for MRSA and 0.25mg/L and 1.0ug/ml for Streptococcus pyogenes for radezolid and linezolid, respectively. MIC90 is defined as the minimum inhibitory concentration necessary to inhibit the growth of 90 percent of the bacteria.

"We are pleased to report that our novel oxazolidinone, radezolid, may provide a safe and more potent alternative to the only currently marketed drug in this antibiotic class," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "In particular, radezolid offers a broader spectrum that includes atypicals an
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...ificance of AHCC for maintaining a healthy immune ...-- A recently published study in Nutrition and Ca...dical University in Osaka, Japan has shown that AH...mune function by increasing the number of dendriti...stem responsible for presenting foreign substances...
(Date:1/6/2009)...Mass., Jan. 6 Cequent Pharmaceutic...s to deliver RNAi-based treatments to prevent and ...s recently completed a successful toxicology study...tk RNAi therapeutic targeting the primary oncogene...us polyposis). FAP is an inherited gastrointestina...
(Date:1/5/2009)...A, Md., Jan. 5 Micromet,...any developing novel, proprietary,antibodies for ...ne diseases,provides an outlook on key events an...ntends to provide an update on its research and de... -- April 12 to 16, 2009: Update on several pre...
(Date:12/29/2008)...d., Dec. 29 The winner ... Protection was announced today by Dr. Peter G. Go...rovement Institute. , , The winner of the annu...rson Cancer Center -- for its best practice " IN...m provides for 1) enhanced human subjects protecti...
Breaking Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 52008 Human Research Protection Award Recipients Announced 2URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 1URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 2URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 3URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards 29324 4Protect Your Family From The Silent Killer This Winter 29321 1Protect Your Family From The Silent Killer This Winter 29321 2Protect Your Family From The Silent Killer This Winter 29321 3Study improves recovery for mothers with depression 29317 1Medicare coding for maggots and maggot therapy 5791 1Medicare coding for maggots and maggot therapy 5791 2Medicare coding for maggots and maggot therapy 5791 3
...May 02, 2007 /PRNewswire-FirstCall/ --,Genelabs Te...on was,made today at the 20th International Confer...ngs, California, on a,non-nucleoside hepatitis C v...labs. , The oral presentation was given by Christo...istry at Genelabs, entitled,"GL59728: A Potent All...
... WIRE)--May 4, 2007 - Argos Therapeutics,today ann...essive,properties of soluble CD83 at the 7th Joint...ncisco, May 5-9. The presentations,will be made in...f,Western Ontario., "These data suggest that solub...lantation, and that it can also act,synergisticall...
Other Medicine Technology:Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
(Date:1/8/2009)...Jude study could shape new treatments for secondar...ire-USNewswire/ -- Scientists at St. Jude Children...ctive treatment for bacterial pneumonia following ...ycin and azithromycin, which kill bacteria by inhi... than a standard first-line treatment with the "be...
(Date:1/8/2009)...red bad cholesterol more effectively than Zocor ,...fter nearly a year of review, U.S. health official...use of the controversial cholesterol-lowering drug...on said there was no significant difference in car...rin and patients taking the drug Zocor. , But, ...
(Date:1/8/2009)... Jan. 8 Hanger Orthopedi...e that throughout the fourth quarter of 2008 it ac..., Rocky Mountain Orthotic-Prosthetics Center, Ries...rst Coast Orthotics & Prosthetics, and Orthope...ns add patient care centers to existing markets in...
(Date:1/8/2009)...CO, Jan. 8 Medivation, I...Hung, M.D., president and chief,executive officer...thcare,Conference on Wednesday, January 14, at 10...otel in San Francisco. , Dr. Hung will prov...velopment programs for Dimebon for Alzheimer,s and...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
... expert, the way one sneezes or the sound that com...ualities of a person.// Patti A. Wood, an Atlanta-...r Benadryl, said a sneeze could offer a revealing ...ty, reported the online edition of ABC News. Wood...
... of the Irish Medical Organization (IMO) has expre...lection for Fine Gael// . Previously, Nora Owen, t... The ambitious contestant is seeking the nominatio... is positive about the success in the political pa...
...in grave consequences. People who are in their 60s...ise. This increases their physical function// and ...ead to a loss of functional independence in the co...r. Dennis T. Villareal from Washington University ...
... women aged 60 and younger have an increased susce...red to others. The results of the study are especi...sts of such patients when compared to heart attack... of the study have been published in the April 24 ...
Other Medicine News:Health News:Depression Accompanies Heart Attacks in Younger Women 2
Vannas Capsulotomy scissors angled
Gills-Vannas straight capsulotomy flat handle scissors
Vannas angled capsulotomy round handle scissors
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium.
Medicine Products: